Vivera is an innovative, science-driven pharmaceutical company located in Southern California. Early 2019, Vivera's core business centered around its pharmaceuticals and medical device divisions. Today, the Company has expanded to include advanced diagnostics, medical technologies, medical supplies, biosciences, and neurosciences divisions, each working synergistically to support Vivera's core mission of putting patients first. Vivera's medical technologies division brings innovative solutions to improve medication safety and compliance and enable more effective communication throughout the medication supply chain. Within this division, the Company holds patents on ZICOH, a high-tech, intelligent, dose-controlled medical device. It has also received a Notice of Allowance for its portable telemedicine station, MDZone. Vivera has supplied needed medical products throughout the pandemic and beyond through its medical supplies division. The Company has global exclusivity within its biosciences division to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use. Vivera Neurosciences utilizes TABMELT technology to expand therapies for various psychiatric and neurological conditions. The Company recently executed a Letter of Intent to enter a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), an Institute within the National Institutes of Health (NIH). The collaboration aims to identify therapeutic agents for the potential treatment of stuttering disorders. From day one, Vivera's mission has been to support the needs of our most underserved communities, finding new and innovative ways to assist patients and medical providers. From the opioid crisis to mental health and beyond, the Company strives to fulfill its purpose and promise toward patient-centric research and development that puts the total health of the patient front and center.